Immunic, Inc. (IMUX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Immunic reported revenue of $0. Net income was -$97.2M, or -$6.20 per diluted share. Operating activities generated -$85.8M of cash, leaving -$86.0M of free cash flow. At fiscal year end, Immunic held $24.1M in total assets against $30.7M in total liabilities, including $15.5M of cash and equivalents.
Open the full interactive Immunic financials → Quarterly statements, key ratios, valuation history and price charts.
Immunic Key Stats
| Share Price | $6.89 |
|---|---|
| Market Cap | $292.9M |
| 52-Week Range | $5.10 – $16.90 |
| Shares Outstanding | 42.5 million (basic, 2026 Q2) |
Immunic Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$49.0M | -$91.7M | -$119.5M | -$99.2M | -$98.1M | -$103.2M |
| Pre-Tax Income | -$44.0M | -$92.9M | -$120.4M | -$93.6M | -$100.5M | -$97.2M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$44.0M | -$92.9M | -$120.4M | -$93.6M | -$100.5M | -$97.2M |
| Diluted EPS | -$28.10 | -$39.30 | -$37.80 | -$21.10 | -$10.00 | -$6.20 |
Immunic Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$25.6M | -$19.3M | -$32.6M | -$34.1M |
| Diluted EPS | -$1.30 | -$0.12 | -$1.08 | -$0.80 |
Immunic Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $127.5M | $86.9M | $106.7M | $46.7M | $35.7M | $15.5M |
| Current Assets | $133.7M | $105.0M | $125.9M | $52.5M | $39.3M | $22.9M |
| Total Assets | $167.9M | $139.1M | $127.8M | $54.3M | $40.9M | $24.1M |
| Current Liabilities | $8.4M | $11.4M | $13.1M | $24.7M | $22.2M | $30.6M |
| Total Liabilities | $9.1M | $12.0M | $14.1M | $25.4M | $22.4M | $30.7M |
| Shareholders' Equity | $158.8M | $127.1M | $113.7M | $28.9M | $18.4M | -$6.7M |
Immunic Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$46.1M | -$83.2M | -$65.1M | -$70.8M | -$84.8M | -$85.8M |
| Cash From Investing | -$146,000 | -$67,000 | -$9.7M | $9.5M | -$264,000 | -$161,000 |
| Cash From Financing | $144.4M | $42.8M | $95.8M | $1.0M | $74.5M | $65.6M |
| Free Cash Flow | -$46.3M | -$83.3M | -$65.3M | -$71.2M | -$85.0M | -$86.0M |
Figures from Immunic's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Immunic financials page for every line item.
Immunic Company Profile
| Ticker | IMUX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, United States |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001280776 |
Frequently Asked Questions
What was Immunic's revenue in fiscal 2025?
Immunic (IMUX) reported revenue of $0 for fiscal 2025.
What is Immunic's annual revenue history?
Immunic's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Immunic's net income in fiscal 2025?
Immunic reported net income of -$97.2M for fiscal 2025.
What was Immunic's earnings per share (EPS) in fiscal 2025?
Immunic's diluted EPS was -$6.20 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Immunic generate in fiscal 2025?
Immunic generated -$86.0M of free cash flow in fiscal 2025.
What was Immunic's revenue last quarter?
In its most recent reported quarter (2026 Q2), Immunic reported revenue of $0.
How many shares of Immunic are outstanding?
Immunic reported a weighted average of 42.5 million basic shares outstanding in 2026 Q2.
What is Immunic's market cap?
Based on its latest closing price, Immunic (IMUX) has a market capitalization of about $292.9M.
When does Immunic's fiscal year end?
Immunic's fiscal year end, as registered with the SEC, is December 31.
Where is Immunic headquartered?
Immunic lists its business address in New York, United States in its SEC filings.